These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16251293)

  • 21. Pharmacokinetics of caspofungin in ICU patients.
    Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
    J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of caspofungin therapy in children with invasive fungal infections.
    Merlin E; Galambrun C; Ribaud P; Blanc T; Michel G; Auvrignon A; Stéphan JL
    Pediatr Infect Dis J; 2006 Dec; 25(12):1186-8. PubMed ID: 17133169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.
    Marr KA; Hachem R; Papanicolaou G; Somani J; Arduino JM; Lipka CJ; Ngai AL; Kartsonis N; Chodakewitz J; Sable C
    Transpl Infect Dis; 2004 Sep; 6(3):110-6. PubMed ID: 15569226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
    Wagner C; Graninger W; Presterl E; Joukhadar C
    Pharmacology; 2006; 78(4):161-77. PubMed ID: 17047411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
    Groll AH; Attarbaschi A; Schuster FR; Herzog N; Grigull L; Dworzak MN; Beutel K; Laws HJ; Lehrnbecher T
    J Antimicrob Chemother; 2006 Mar; 57(3):527-35. PubMed ID: 16431856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antifungal drugs and the pediatric cancer patient: current status of clinical development.
    Groll AH; Lehrnbecher T
    Klin Padiatr; 2005; 217(3):158-68. PubMed ID: 15858708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
    van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
    Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients.
    Saner F; Gensicke J; Rath P; Fruhauf N; Gu Y; Paul A; Radtke A; Malagó M; Broelsch C
    Infection; 2006 Dec; 34(6):328-32. PubMed ID: 17180587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
    Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of caspofungin in solid organ transplant recipients.
    Petrovic J; Ngai A; Bradshaw S; Williams-Diaz A; Taylor A; Sable C; Vuocolo S; Kartsonis N
    Transplant Proc; 2007 Dec; 39(10):3117-20. PubMed ID: 18089335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
    Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
    Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
    Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
    Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.
    Koo A; Sung L; Allen U; Naqvi A; Drynan-Arsenault J; Dekker A; Maloney AM; Dupuis LL
    Pediatr Infect Dis J; 2007 Sep; 26(9):854-6. PubMed ID: 17721388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacology and clinical use of caspofungin.
    Hope WW; Shoham S; Walsh TJ
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):263-74. PubMed ID: 17428155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
    Agarwal MB; Rathi SA; Ratho N; Subramanian R
    J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.